BR112012021884B8 - Composto, composição farmacêutica e método para afetar a coagulação sanguínea ou coagulação de plasma sanguíneo - Google Patents
Composto, composição farmacêutica e método para afetar a coagulação sanguínea ou coagulação de plasma sanguíneoInfo
- Publication number
- BR112012021884B8 BR112012021884B8 BR112012021884A BR112012021884A BR112012021884B8 BR 112012021884 B8 BR112012021884 B8 BR 112012021884B8 BR 112012021884 A BR112012021884 A BR 112012021884A BR 112012021884 A BR112012021884 A BR 112012021884A BR 112012021884 B8 BR112012021884 B8 BR 112012021884B8
- Authority
- BR
- Brazil
- Prior art keywords
- clotting
- compounds
- pharmaceutical composition
- thrombosis
- blood
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 206010053567 Coagulopathies Diseases 0.000 title abstract 2
- 230000023555 blood coagulation Effects 0.000 title abstract 2
- 230000035602 clotting Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000002381 plasma Anatomy 0.000 title 1
- 208000007536 Thrombosis Diseases 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 238000007887 coronary angioplasty Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
compostos, composição farmacêutica e método para prevenir e tratar uma condição, tal como uma trombose indesejada, em um mamífero, e método para inibir a coagulação de uma amostra biológica. a invenção se refere a uma nova classe de compostos, aos seus sais farmaceuticamente aceitáveis e às suas composições farmaceuticamente aceitáveis que são efetivas como inibidores seletivos do fator xa, ambos no estado isolado e em um complexo com outras proteínas. os compostos da invenção podem ser usados para tratar e prevenir doenças, tais como síndrome coronariana aguda, infarto do miocárdio, angina instável, angina refratária, trombose causada por terapia pós-trombolítica ou angioplastia coronariana, síndrome cerebrovascular mediada por isquemia aguda, acidente vascular cerebral trombótico e outras doenças, em humanos e em outros mamíferos, associadas como problemas na coagulação sanguínea.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU201000506 | 2010-02-03 | ||
| EA201000506A EA015918B1 (ru) | 2010-03-03 | 2010-03-03 | УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa |
| PCT/RU2011/000129 WO2011108963A1 (en) | 2010-03-03 | 2011-03-02 | Urethanes, ureas, amidines and related inhibitors of factor xa |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012021884A2 BR112012021884A2 (pt) | 2016-05-24 |
| BR112012021884B1 BR112012021884B1 (pt) | 2021-10-13 |
| BR112012021884B8 true BR112012021884B8 (pt) | 2021-12-28 |
Family
ID=44542428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012021884A BR112012021884B8 (pt) | 2010-03-03 | 2011-03-02 | Composto, composição farmacêutica e método para afetar a coagulação sanguínea ou coagulação de plasma sanguíneo |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9708265B2 (pt) |
| EP (1) | EP2542529B1 (pt) |
| JP (1) | JP6078707B2 (pt) |
| KR (1) | KR101771760B1 (pt) |
| CN (1) | CN102971294B (pt) |
| AU (1) | AU2011221601B2 (pt) |
| BR (1) | BR112012021884B8 (pt) |
| CA (1) | CA2791875C (pt) |
| CY (1) | CY1122645T1 (pt) |
| DK (1) | DK2542529T3 (pt) |
| EA (1) | EA015918B1 (pt) |
| HK (1) | HK1182700A1 (pt) |
| HR (1) | HRP20192125T1 (pt) |
| HU (1) | HUE047249T2 (pt) |
| IL (1) | IL221727A (pt) |
| LT (1) | LT2542529T (pt) |
| MX (1) | MX2012009976A (pt) |
| NZ (1) | NZ602769A (pt) |
| PL (1) | PL2542529T3 (pt) |
| PT (1) | PT2542529T (pt) |
| SI (1) | SI2542529T1 (pt) |
| UA (1) | UA107106C2 (pt) |
| WO (1) | WO2011108963A1 (pt) |
| ZA (1) | ZA201207345B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014003153A1 (ja) * | 2012-06-28 | 2014-01-03 | 協和発酵キリン株式会社 | 置換アミド化合物 |
| RU2698202C2 (ru) * | 2016-06-01 | 2019-08-23 | Закрытое акционерное общество "ФАРМА ВАМ" | СПОСОБ ПОЛУЧЕНИЯ ПРЯМОГО ИНГИБИТОРА ФАКТОРА Ха |
| EA030138B1 (ru) * | 2016-06-15 | 2018-06-29 | Общество С Ограниченной Ответственностью "Фармадиол" | Фармацевтические композиции, включающие антикоагулянт n-(5-хлорпиридин-2-ил)-2-({4-[этанимидоил(метил)амино]бензоил}амино)-5-метилбензамид |
| RU2659161C1 (ru) | 2017-11-17 | 2018-06-28 | Общество С Ограниченной Ответственностью "Ива Фарм" | Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид |
| EA201800084A1 (ru) * | 2018-01-19 | 2019-07-31 | Общество С Ограниченной Ответственностью "Фармадиол" | НОВЫЕ АМИДИНЫ-ИНГИБИТОРЫ ФАКТОРА Ха |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588587A (en) | 1983-03-01 | 1986-05-13 | Pennsylvania Hospital | Method of treatment to inhibit metastasis |
| RU2154633C2 (ru) | 1994-12-02 | 2000-08-20 | Яманоути Фармасьютикал Ко., Лтд. | Производные амидинонафтила и фармацевтическая композиция |
| US5849759A (en) | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
| EP0946508B1 (en) | 1996-12-23 | 2009-09-23 | Bristol-Myers Squibb Pharma Company | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS |
| AU8747598A (en) | 1997-08-27 | 1999-03-16 | Kissei Pharmaceutical Co. Ltd. | 3-amidinoaniline derivatives, activated blood coagulation factor x inhibitors, and intermediates for producing both |
| IL155155A0 (en) | 1999-09-17 | 2003-10-31 | Cor Therapeutics Inc | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| AU2108601A (en) * | 1999-12-15 | 2001-06-25 | Axys Pharmaceuticals, Inc. | Salicylamides as serine protease inhibitors |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE60115394T2 (de) * | 2000-02-29 | 2006-10-19 | Millennium Pharmaceuticals, Inc., Cambridge | Benzamide und ähnliche inhibitoren vom faktor xa |
| DE10063008A1 (de) * | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| AU2002350217A1 (en) * | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| WO2006070878A1 (ja) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | カルボン酸誘導体またはその塩 |
| DE102005042583A1 (de) * | 2005-09-08 | 2007-03-15 | Bayer Healthcare Ag | Iminooxazolidin-Derivate und ihre Verwendung |
| NZ592533A (en) * | 2005-11-08 | 2012-08-31 | Millennium Pharm Inc | METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR |
| RU2452484C2 (ru) * | 2006-12-08 | 2012-06-10 | Милленниум Фармасьютикалз, Инк. | Стандартные лекарственные препараты и способы лечения тромбоза пероральным введением ингибитора фактора ха |
-
2010
- 2010-03-03 EA EA201000506A patent/EA015918B1/ru unknown
-
2011
- 2011-02-03 UA UAA201211358A patent/UA107106C2/ru unknown
- 2011-03-02 SI SI201131816T patent/SI2542529T1/sl unknown
- 2011-03-02 MX MX2012009976A patent/MX2012009976A/es active IP Right Grant
- 2011-03-02 AU AU2011221601A patent/AU2011221601B2/en active Active
- 2011-03-02 HU HUE11750982A patent/HUE047249T2/hu unknown
- 2011-03-02 WO PCT/RU2011/000129 patent/WO2011108963A1/en active Application Filing
- 2011-03-02 EP EP11750982.8A patent/EP2542529B1/en active Active
- 2011-03-02 PL PL11750982T patent/PL2542529T3/pl unknown
- 2011-03-02 PT PT117509828T patent/PT2542529T/pt unknown
- 2011-03-02 CA CA2791875A patent/CA2791875C/en active Active
- 2011-03-02 KR KR1020127025881A patent/KR101771760B1/ko active IP Right Grant
- 2011-03-02 LT LT11750982T patent/LT2542529T/lt unknown
- 2011-03-02 CN CN201180011928.4A patent/CN102971294B/zh active Active
- 2011-03-02 NZ NZ602769A patent/NZ602769A/en unknown
- 2011-03-02 DK DK11750982.8T patent/DK2542529T3/da active
- 2011-03-02 BR BR112012021884A patent/BR112012021884B8/pt active IP Right Grant
- 2011-03-02 JP JP2012556036A patent/JP6078707B2/ja active Active
-
2012
- 2012-08-30 IL IL221727A patent/IL221727A/en active IP Right Grant
- 2012-08-30 US US13/599,038 patent/US9708265B2/en active Active
- 2012-10-01 ZA ZA2012/07345A patent/ZA201207345B/en unknown
-
2013
- 2013-08-26 HK HK13109973.7A patent/HK1182700A1/xx unknown
-
2019
- 2019-10-03 CY CY20191101032T patent/CY1122645T1/el unknown
- 2019-11-26 HR HRP20192125TT patent/HRP20192125T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012021884B8 (pt) | Composto, composição farmacêutica e método para afetar a coagulação sanguínea ou coagulação de plasma sanguíneo | |
| BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
| BR112014010576B8 (pt) | compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos | |
| BR112015020350A2 (pt) | derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd | |
| BR112015002293A2 (pt) | di-hidropiridona pi como inibidores do fator xia | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112012027062B8 (pt) | composto, processo para a preparação de um composto e usos do mesmo | |
| BR112014030812A2 (pt) | "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr" | |
| CO6551666A2 (es) | Macrociclos como inhibidores del factor de coagulacion (fxia) | |
| BR112017002221A2 (pt) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| BR112012012906A2 (pt) | triazolopiridinas | |
| BRPI0919873B8 (pt) | compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas | |
| DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| BR112014002202A2 (pt) | macrociclos como inibidores de fator xia | |
| BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| BR112013005622A2 (pt) | heteroaril metil amidas | |
| CO6660497A2 (es) | Derivados del ácido nft-2-ilacético para tratar el sida | |
| BR112014000240A2 (pt) | derivados de benzilamina como inibidores de calicreína plasmática | |
| BR112017009701A2 (pt) | composto e métodos para a preparação de um composto | |
| BR112013025519A2 (pt) | composição farmacêutica | |
| BR112017018328A2 (pt) | anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo | |
| NO20085212L (no) | Nye pyridinanaloger | |
| BRPI1010970A2 (pt) | solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento | |
| BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
| BR112017011124A2 (pt) | 1-[2-(aminometil)benzil]-2-tioxo-1,2,3,5-tetraidro-4h-pirrolo[3,2-d]pirimidin-4-ona como inibidor da mieloperoxidase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: PHARMADIALL, LTD. (RU) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2649 DE 13/10/2021 QUANTO AO INVENTOR. |